Ascendis Pharma A/S vs TotalEnergies SE — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.78B), while TotalEnergies SE trades at $86.9 (market cap $193.69B). The key difference: TotalEnergies SE is far larger — about 11.5× Ascendis Pharma A/S's market cap, and TotalEnergies SE pays a 4.82% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | TTE | |
|---|---|---|
Market Cap | $16.78B | $193.69B |
Sector | Health | Energy |
52-Week High | $277.18 | $93.60 |
52-Week Low | $189.74 | $57.39 |
Enterprise Value | $17.15B | $224.68B |
Dividend Yield | — | 4.82% |
Trailing returns across standard periods
Latest headlines on both assets
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →